Journal
ONCOTARGET
Volume 7, Issue 13, Pages 17103-17110Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7931
Keywords
123B9; EphA2; targeted delivery; drug-conjugates; gemcitabine
Categories
Funding
- NIH
- NCI [CA138390, CA081534, CA149668, CA168517, CA191515]
- NIH institute NIAAA [AA11999]
- NIH institute NCI [CA163200]
- NIH institute Department of Veterans Affairs
- NIH Cancer Center [CA030199]
Ask authors/readers for more resources
First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine. In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit. However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity. In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent. We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors. Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available